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Procainamide, Disopyramide and Quinidine: Discordant
Antiarrhythmic Effects During Crossover Comparison in Patients
With Inducible Ventricular Tachycardia
D. GEORGE WYSE, MD , PHD, FACC , L. BRENT MITCHELL, MD, HENRY J. DUFF, MD
Calgary. Alberta , Canada
A crossover comparison of intravenous procainamide,
disopyramide and quinidine was made in 32 patients.
All three drugs had dosage-related effects on electro-
cardiographic intervals, refractory periods and cycle
length of ventricular tachycardia. Significant linear re-
lations between serum drug levels and changes in re-
fractory periods and ventricular tachycardia cycle length
were also observed. Ventricular tachycardia was no longer
inducible on at least one drug in II patients but con-
cordance of this effect on both of the others was 36%
and on either of the others it was 45%. Ventricular
tachycardia remained inducible on at least one drug in
28 patients and concordance of this effect on both of the
others was 75% and on either of the others was 79%.
Classification of antiarrhythmic agents into pharmacologi-
cally related subgroups is useful, particularly for the purpose
of teaching. The most widely used classification scheme is
based on the effects of drugs on cardiac action potentials
of single cells from normal animal hearts (I). In this system,
procain amide, disopyramide and quinidine are grouped to-
gether in class lA, Such schemes have limitations and their
clinical applicability is unproved . The effects of these drugs
on single cell action potentials of normal cardiac tissue are
not the same (2). Other potential limitations (3,4) include :
I) different direct cardiac effects on normal and diseased
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Continued inducibility on quinidine, the drug producing
the greatest electrophysiologic effects, was the best in-
dividual predictor of continued inducibility on the oth-
ers. Subdivision of continued inducibility into 1) easier
to induce, 2) inducibility unchanged, or 3) harder to
induce dramatically decreased concordance of this ef-
fect.
Thus the antiarrhythmic effects of these drugs are
discordant in individual patients despite electrophysio-
logicsimilarities. Nevertheless,continued inducibilityafter
high dosages of anyone of these drugs is clinically useful
for screening for continued inducibility on the others
and this is dose-related rather than drug specific.
(J Am Coil Cardiol 1987;9:882-9)
myocardium; 2) different indirect cardiac effects (vasodi-
lation , autonomic blockade); and 3) different pharmacoki-
netic characteristics (protein binding, formation of active
metabolites). These considerations have prompted retro -
spective clinical studies with conflicting results (5-7). These
studies utilized a mixture of intravenous and oral dosage
forms that are not always equivalent (8,9) and probably
contributed to their conflicting results. Accordingly, a pro-
spective crossover study was undertaken to assess the con-
cordance of electrophysiologic and antiarrhythmic effects
of these three drugs in patient s with inducible ventricular
tachycardia (10). To optimize the assessment of concentra-
tion-re sponse relation s and to minimize pharmacokinetic
confounders such as active metabolite formation, the drug s
were administered as a series of loading and maintenance
intravenous infusions .
Methods
Selection of patients. Thirty-two patients with induc-
ible, ventricular tachycardia/fibrillation at an antiarrhythmic
drug-free catheter electrophysiologic study participated in
this investigation. Inclusion required informed consent, re-
producible (2':twice) ventricular tachycardia/fibrillation in-
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duction at baseline and repeat ventricular tachycar-
dia/fibrillation induction immediately before each drug
infusion. Patients without documented spontaneous ven-
tricular tachycardia/fibrillation were included only when
sustained unimorphic ventricular tachycardia was induced
and the patient's symptoms were reproduced.
Study design. Concentration-response relations were
determined for all three drugs (procainamide, disopyramide
and quinidine). After a baseline drug-free evaluation, each
patient received each medication on separate days. Drugs
were not administered in any particular order but their
administration was not formally randomized. Testing of each
drug was separated by a minimum of 24 and a maximum
of 72 hours. Only when repeat testing of the next drug was
performed 24 hours after the previous one were serum levels
of the first drug measured at the second test. The previous
drug was detectable in the serum of only two patients, and
in these two the levels were well below the lower limit of
the therapeutic range. The electrophysiologic effects and
antiarrhythmic activity of each drug were assessed by trans-
venous catheter electrophysiologic study using the same
pacing site (right ventricular apex in all instances) at which
ventricular tachycardia was induced just before drug admin-
istration. Each antiarrhythmic drug was administered as a
series of loading and maintenance intravenous infusions de-
signed to produce two stable serum concentrations. The
higher dose was administered only if ventricular tachycardia
remained inducible on the low dose. The concordance of
antiarrhythmic activity was assessed in this crossover de-
stgn.
Procedures. Electrophysiologic testing was performed
using commonly employed pacing and extrastimulus tech-
niques. Patients were studied in the fasting state after all
medications with known electrophysiologic effects had been
discontinued for at least five half-lives. Surface electrocar-
diographic leads I, aVF and V I were recorded simulta-
neously with intracardiac electrograms from the high right
atrium, His bundle site and right ventricular apex.
Standard definitions were used to determine electrocar-
diographic intervals obtained at a paper speed of 100 mm/s.
The rate-corrected QT interval was calculated from the for-
mula QTc = QT/VRR(s). Ventricular effective and func-
tional refractory periods were determined for single (S2),
double (S3) and triple (S4) extrastimuli at basic pacing cycle
lengths of 600, 500 and 400 ms. The SIS2 interval was
progressively shortened by 10 ms until ventricular capture
was lost. It was increased again (usually by 10 to 20 ms)
until reliable ventricular capture was reestablished and then
the S2S3 interval was progressively shortened by 10 ms until
ventricular capture was lost. The same process was followed
with the S3S4 interval after similarly setting the S2S3 inter-
val.
Ventricular tachycardia/fibrillation induction was at-
tempted with a protocol using right ventricular stimuli of 2
ms duration and an intensity of at least 10 times diastolic
threshold. We have shown in a previous study (II) that no
change in ventricular tachycardia inducibility accompanied
changes in stimulus intensity from twice to 10 times the
threshold. Single, double and triple extrastimuli were ap-
plied at basic pacing cycle lengths of 600, 500 and 400 ms.
If necessary, bursts of rapid ventricular pacing at cycle
lengths of 300 to 240 ms were used after completion of the
extrastimulus portion of the protocol. This protocol is sim-
ilar to that used by a number of other laboratories (12,13).
Sustained ventricular tachycardialjibrillation was de-
fined as a continuous ventricular rhythm with a cycle length
of <500 rns, lasting for> 30 seconds or requiring premature
termination because of serious hemodynamic compromise.
During drug therapy, completion of the entire induction
protocol without production of five or more consecutive
ventricular depolarizations at a cycle length of <500 ms
was taken to indicate a complete antiarrhythmic response.
Partial antiarrhythmic response was defined as an increase
in the number of extrastimuli required to induce ventricular
tachycardia/fibrillation. Completion of the extrastimulus
portion of the protocol with subsequent ventricular tachy-
cardia/fibrillation induction by rapid burst pacing was also
considered to be a partial antiarrhythmic response. The term
"harder to induce" will refer to either of these partial re-
sponses. The term "easier to induce" will refer to the ob-
servation that fewer extrastimuli were required to induce
ventricular tachycardia/fibrillation. No patient required rapid
burst pacing to induce ventricular fibrillation at the drug-
free study.
Drugs. The lower dosage procainamide infusions were
0.25 mg/kg per min for 30 minutes, then 0.05 mg/kg per
minute for a minimum of IS minutes. The higher dosage
procainamide infusions were an additional 0.15 mg/kg per
min for 10 minutes, then 0.075 mg/kg per min for a min-
imum of IS minutes. Similarly, the lower dosage disopyr-
amide infusions were 0.14 mg/kg per min for 25 minutes,
then 0.01 mg/kg per min for at least IS minutes. The higher
dosagedisopyramide infusions were an additional 0.06 mglkg
per min for 5 minutes, then 0.0 IS mg/kg per min for at
least 15 minutes. The higher dosage of disopyramide was
not given when the drug-free left ventricular ejection frac-
tion (gated nuclear angiogram) was <35%. The quinidine
infusions were the same as those used in previous studies
from this laboratory (14). Brieflythe lower dosage quinidine
infusions were 0.22 and then 0.11 mg/kg per min, each
given for 25 minutes. The higher dosage quinidine infusions
were an additional 0.17 and then 0.14 mg/kg per min, each
given for 25 minutes.
Electrophysiologic measurements began no sooner than
IS minutes after the start of the last infusion for each dosage
level. To verify constant serum levels, samples were ob-
tained at the beginning and end of each series of electro-
physiologic measurements. The serum drug levels reported
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Figure 1. Cumulative proportion of patients who had a complete
response toprocainamide (P), disopyramide (0) and quinidine (Q)
at low and high drug concentrations (Conc.), The vertical axis is
the proportion (% response) of the patients whose ventricular
tachycardia became noninducible and vertical lines represent the


















here and used for statistical purposes are the average of
these two determinations. Procainamide, disopyramide and
quinidine were measured using EMIT assays.
Data analysis. Continuous data are reported as the
mean ± I SD. Proportions are presented ± SEE. Standard
deviations and standard errors of the estimate are omitted
from the figures when they overlap. Statistical analysis was
done by chi-square technique for paired dichotomous data
(Cochran's and McNemar tests). To compare continuous
data within one drug treatment, the paired t test using Bon-
ferroni's correction (15) was used on complete data (that
is, data available for baseline, low and high drug dosages)
and one-way analysis of variance and Tukey's test was used
to include all data. To compare continuous data between
drug treatments, multivariate analysis of variance using
Bonferroni's correction for multiple comparisons was ap-
plied. The relations between serum drug levels and electro-
physiologic measurements were examined by linear regres-
sionand linearity was tested by analysis of residuals. Programs
from the Statistical Package for Social Sciences (version
SPSSx) (16) were utilized in data analysis. The null hy-
pothesis was rejected when probability (p) was < 0.05.
Results
Study patients. All 32 patientshad reproducibly induced
ventricular tachyarrhythmias as the main criterion for entry
into the study. Their clinical characteristics are outlined in
Table I. Most patients were men with coronary artery dis-
ease.
Inducibility of ventricular tachyarrhythmias: re-
sponse rate. The overall antiarrhythmicactivity of the three
drugs, as determined by effects on ventricular tachycar-
dia/fibrillation inducibility, were not significantly different.
Cumulative response rates at low and high concentrations
of each of the three drugs are depicted in Figure I. The
total number and proportion of patients who had a complete



























response to each drug were: five (16 ± 7%) for procain-
amide, six (19 ± 7%) for disopyramide and nine (28 ±
8%) for quinidine. Eight patients with a very low left ven-
tricularejection fractions «0.35) did not receive the higher
disopyramide dosage. In addition to the complete re-
sponders, there were some patients who had a "partial"
response in that a greater number of extrastimuli (or burst
pacing in two patients) were required to induce ventricular
tachycardia/fibrillation (see Methods).The cumulativenum-
bers and proportions of patients with a partial response to
each drug were: six (19 ± 7%) for procainarnide, six (19
± 7%) for disopyramide and six (19 ± 7%) for quinidine.
Combination of complete and partial responders results in
cumulative numbers and proportions of patients who had
potential antiarrhythmic effects as follows: II (34 ± 7%~
for procainamide, 12 (38 ± 9%) for disopyramide and 15
(47 ± 9%) for quinidine. The remainder of the patients
showed no evidence of a potential antiarrhythmic response
to any of the three drugs.
No difference in the potential for a proarrhythmic effect
was seen in comparison of the cumulative numbers and
proportions requiring fewer extrastimuli to induce ventric-
ular tachycardia (procainarnide, seven [22 ± 7%]; diso-
pyramide, six [19 ± 7%]; quinidine, seven [22 ± 7%D.
The drug-free ventricular tachyarrhythmiacycle length and
refractory periods tended to be shorter in those patients who
were complete responders to each of the three drugs, but
significant differences were seen only in the comparison of
disopyramide responders and nonresponders (Table 2).
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Table 2. Drug-Free Electrophysiologic Measurements
Response to Response to Response to
Procainamide Disopyramide Quinidine
NI I NI I NI I
Measurement (n = 5) (n = 27) (n = h) (n = 26) (n = 9) (n = 23)
QRS interval 116 ± 36 115 ± 31 104 ± 33 119 ± 31 118 ± 33 115 ± 31
QTc interval 448 ± 22 450 ± 29 452 ± 21 449 ± 29 436 ± 23 455 ± 28
VTCL 217 ± 21 244 ± 42 208 ± 20* 247 ± 41 224 ± 20 246 ± 45
VERP 224 ± 24 243 ± 48 215 ± 22 245 ± 48 232 ± 21 244 ± 53
VFRP 257 ± 16 271 ± 29 246 ± 15* 274 ± 22 268 ± 21 270 ± 24
*p< 0.05 NI versus I. All values are ms ± SO and were obtained just before drug administration. Patients
are grouped according to subsequent antiarrhythmic response to each drug. I = remained inducible on this
drug; NI = became noninducible on this drug; VERP = ventricular effective refractory period of S2 at pacing
interval of 500 InS; VFRP = ventricular functional refractory period of S2 at pacing interval of 500 ms:
VTCL = ventricular tachyarrhythmia cycle length.
Inducibility of ventricular tachyarrhythmias: discor-
dance of antiarrhythmic drug response. Although overall
group response rates to these three drugs were not different,
their antiarrhythmic effects were discordant within individ-
uals. Figures 2 and 3 show the individual concordance and
discordance of effect on ventricular tachycardia/fibrillation
inducibility. A total of II patients became noninducible on
at least one drug (Fig. 2). Six responded to only a single
drug (four to quinidine, two to disopyramide) and five re-
sponded to two or more (one to procainamide/quinidine,
four to procainamide/disopyramide/quinidine). Thus, the
concordance of drug response for complete responders may
be stated: a response to anyone drug was associated with
a response to any of the others in 45% and to both of the
others in 36%.
Inducibility of ventricular tachyarrhythmias: con-
cordance of antiarrhythmic drug resistance. Because only
4 patients responded to all three drugs the remaining 28
patients will show the frequency of concordance of drug
resistance. Twenty-one patients were resistant to all three
drugs, 6 patients to two drugs and I patient to a single drug.
Thus, the concordance of drug resistance may be stated:
resistance to anyone drug was associated with resistance
to any of the others in 79% and to all the others in 75%.
Inducibility of ventricular tachyarrhythmias: discor-
dance of number of extrastimuli used. In the preceding
analysis of concordance of drug resistance, no allowance is
made for the three subcategories of drug resistance repre-
Figure 3. Concordance of drug resistance to procainamide (P),
disopyramide (D) and quinidine (Q) subcategorized by whether a
lesser (easier to induce, n = 16, upper panel), the same (induc-
ibility unchanged, n = 22, middle panel) or a greater (harder to
induce, n = 14, lower panel) number of extrastimuli were used.
Vertical axes represent the number of patients. Letters below
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Figure 2. Concordance of antiarrhythmic effectsof procainarnide
(P), disopyramide (D)andquinidine (Q) in II responders. Vertical
axis represents the number of patients. Letters below each bar
indicate whether the response was to one, two or all three drugs.
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sented by continued ventricular tachycardia/fibrillation in-
ducibility with the same number, with fewer and with more
extrastimuli compared with baseline. These subcategory
concordance data are shown in Figure 3. Inducibility with
fewer extrastimuli on anyone drug was associated with
inducibility with fewer extrastimuli on either of the others
in 25% and on both of the others in 0%. Unchanged in-
ducibility on anyone drug was associated with unchanged
inducibility on either of the others in 59% and on both of
the others in 14%. Inducibility with more extrastimuli on
anyone drug was associated with inducibility with more
extrastimuli on either of the others in 29% and on both of
the others in 0%. These subcategory concordances are clearly
lower than the overall concordance of drug resistance. Al-
though the latter may be of clinical utility, the subcategory
concordances more directly address drug similarities and
differences.
In contrast with these results, when one compares the
number of extrastimuli needed to induce ventricular tachy-
cardia/fibrillation in the baseline drug-free studies done in
each patient, the same number of extrastimuli was used for
all three baseline studies in 16 patients; the same number
of extrastimuli was used for two of three baseline studies
in 15additional patients; and in only I patient was a different
number of extrastimuli used at each baseline study. Thus
the concordance of drug-free study results may be stated to
be 97% for any two of three drug-free studies and 50% for
all three drug-free studies.
Serum drug levels. For each drug the average serum
concentration (umol/liter) at the higher dosage was signif-
icantly greater than at the lower dosage: procainamide =
28.6 ± 12.1 versus 20.2 ± 6.9 (p = 0.002); disopyramide
= 13.9 ± 3.7 versus 12.4 ± 2.8 (p = 0.001); and quin-
idine = 13.6 ± 6.5 versus 11.1 ± 6.1 (p < 0.001). Serum
drug concentrations in those patients who became nonin-
ducible were not significantly different from those of pa-
tients whose ventricular tachycardia remained inducible:
procainamide = 24.4 ± 18.3 versus 27.1 ± 10.5 (p =
0.60); disopyramide = 10.9 ± 0.6 versus 13.5 ± 3.5
(p = 0.09); and quinidine 10.2 ± 5.3 versus 12.9 ± 7.4
(p = 0.29). The average variation in serum drug levels
from the beginning to the end of programmed stimulation
ranged from - 5.2 to +4.4%. The details of our pharma-
cokinetically designed quinidine infusion have been previ-
ously reported (II).
Effects on other electrophysiologic measurements. The
effects of these three drugs on surface electrocardiographic
measurements are presented in Figure 4. Each drug affected
each of the surface electrocardiographic intervals equally,
with one exception. The increase in QTc interval caused by
the higher dosage of quinidine was significantly greater than
that caused by the higher dosage of procainamide. The ef-
fects of these three drugs on ventricular tachyarrhythmia






Figure 4. Effects of procainamide (P), disopyramide (0) and
quinidine (Q) on surface electrocardiographic intervals. All ver-
tical axes are in milliseconds and the vertical bars indicate ± I
SO (omitted when there is overlap). Each point is the mean of
values obtained at the baseline drug-free study each day or the
mean of those obtained at either the low or high concentrations
(cone) of each drug. Significant (p < 0.05) differences are indi-
cated as follows: *different from baseline, §high concentration
different from low concentration, •quinidine different from pro-
cainamide.
Figure 5. Each drug prolonged ventricular tachyarrhythmia
cycle length. The effect of quinidine and disopyramide ex-
ceeded that of procainamide at low concentrations. Effects
on ventricular effective and functional refractory periods
were similar to those on ventricular tachyarrhythmia cycle
length. Quinidine effects on refractoriness exceeded those
of procainamide at both concentrations.
There was significantly greater prolongation of the QRS
interval in responders to disopyramide compared with that
in nonresponders (16 ± 8 versus 6 ± 19 ms). Conversely,
there was significantly less prolongation of QRS interval in
responders to quinidine compared with that in nonrespond-
ers (I ± 14 versus 10 ± 12 ms). Procainamide had an
equal effect on the QRS interval of responders and nonre-
sponders (4 ± 9 versus 9 ± 16 ms). There was significantly
greater prolongation of QTc interval in responders to quin-
idine compared with that of nonresponders (86 ± 67 versus
32 ± 54 ms), but this effect was not seen with either of
the other two drugs. No other significant differences were
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Figure 5. Effects of procainamide (P), disopyramide (D) and
quinidine (Q) on ventricular tachycard ia (YT) cycle length . and
ventricular effective (YERP) and functional (YFRP) refractory
periods of S! at ventricular paced cycle lengthof 500ms. All axes
are in ms and vertical bars indicate ± I SD (omitted when there
is overlap). Each point is the mean of values obtained at the
baseline drug-free study each day or the mean of those obtained
at either the low or high concentrations of each drug. Signi ficant
(p < 0.05) differences are indicated as follows: *different from
baseline. *high concentration different from low concentration.
+quinidine different from procainamide, t +disopyramide and
quinidine different from procainamide.
noted among effects of the three drugs on the remaining
electrophysiologic measurements in responders and nonre-
spenders. Thus, when patients were categorized into those
with and those without an antiarrhythmic response, there
was also discordance among the effects of each drug on
other electrophysiologic measurements.
Relations between serum drug levels and changes in
electrophysiologic measurement. Relations between serum
drug concentrations and electrophysiologic measurements
were analyzed by linear regression. Over the wide range of
concentrations tested in this study. all significant concen-
tration-effect relations were linear according to analysis of
residuals. For each drug. statistically signifi cant correlations
were found between serum concentrations and one or more
ventricular refractory periods. For procainamide and quin-
idine there was also a significant correlation between serum
concentration and ventricular tachycardia cycle length. The
strength (r) and statistical significance (p) of the nonsignifi-
cant correlations was enhanced by considering only those
individuals with a drug-induced decrease in sinus cycle length
of ;:::: 50 ms. For example. the linear relations between serum
procainamide concentration and increased ventricular ef-
fective refractory period of S.l had a slope of 1.1 ± 0.8
and an intercept of 004 ± 15.6 (N = 19. r = 0.31, p =
0. 19) when all patients were included. but when only those
with a drug-induced decrease in sinus cycle length were
analyzed. the slope was 204 ± 1.0 and the intercept was
- 30.2 ± 21.0 (N = 12. r = 0.58, P = 0.04). Serum
drug concentrations did notcorrelate significantly withchanges
in any of the surface electrocardiographic intervals.
The changes in ventricular tachyarrhythmia cycle length
and refractoriness were concentration-related and these re-
lations may therefore be used to estimate "electrophysio-
logically equivalent" ranges of serum levels for the three
drugs. Setting an arbitrary' 'therapeutic range" of quinidine
of 7.0 to 15.0 p.mollliter. linear regression indicates " equiv-
alent ranges" of procainamide and disopyramide of 32.8 to
84.0 and 8.2 to 23.0 p.mol/liter . respectively.
Discussion
Previous studies have retrospectively compared the anti-
arrhythmic efficacy of procainamide, disopyramide and
quinidine. Our study is unique in that all patients received
all three drugs, all three drugs were administered using the
same route. concentration-response relations for both anti-
arrhythmic efficacy and other electrophysiologic effects were
evaluated, and baseline measurements, includingventricular
tachycardia/fibrillation inducibility. were repeated before the
administration of each drug. This last point is particularly
important as even negligible lingering blood levels of the
previous drug may have some trivial residual effects when
the next drug is tested.
Antiarrhythmic response rates. Although there were
no significant differences in overall complete response rates
among the three drugs. the response rates to disopyramide
and procainamide tended to be lower than those to quinidine.
This apparent trend may be related to a number of factors.
the most obvious of which is the observation that the achieved
serum concentrations of the three drugs did not produce
precisely equivalent electrophysiologic effects. The quini-
dine levels achieved were higher than those usually reported.
Although the procainamide levels achieved are within the
generally accepted therapeutic range. they are lower than is
sometimes required in patients with chronic ventricular ar-
rhythmias (17.18). These considerations suggest that the
trend in response rates in our study is not only statistically
nonsignificant but also clinically unimportant. Complete re-
sponse rates to the three drugs in our study are similar to
those in previous reports (19) using definitions of response
the same as those used here. Our definition of complete
response is more rigorous than that of other investigators
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(5,6) reporting higher response rates. These higher response
rates are achieved in our study with inclusion of what we
have chosen to term partial responses.
Discordance of antiarrhythmic drug response. De-
spite the apparent similarity of these drugs implied by overall
response rates, there is substantive discordance of individual
responses. The positive concordance rate observed in this
study was 36%. That is, complete responders to anyone
drug have a 36% chance of responding to the other two
drugs. This probability is not significantly different from
the probability of an untested patient responding to anyone
of these drugs (II [34%] of 32). Therefore, at least with
respect to individual antiarrhythmic response, these drugs
are dissimilar. The clinical implication of this observation
is that when it is necessary to change to another drug after
successful antiarrhythmic control with one of the three drugs,
efficacy must be tested on the new drug because the chance
of success after empiric change to either of the other two
is low. This low positive concordance rate could not have
been improved by either higher procainamide dosages or
giving high-dose disopyramide to the patients with marked
left ventricular dysfunction. As seen in Figure 2, only five
patients responded to one or two drugs and could have
improved concordance by responding to both procainamide
or disopyramide in higher dosages. However, four of these
five did indeed receive the higher dosage of disopyramide.
Therefore, although higher dosages of procainamide may
have increased the proportion of patients responding to that
drug, the overall positive concordance rate could only have
improved by a maximum of one patient (up to 45%).
Concordance of antiarrhythmic drug resistance. The
overall negative concordance in this study was 79% (22 of
28). That is, nonresponders to anyone drug have a 79%
chance of not responding to one of the other two. Therefore,
on average, the use of one drug to screen for nonresponse
to the other two would deny 21% of these patients the
opportunity for potentially effective therapy. However, re-
sistance to a specific drug as a predictor of resistance to the
other two ranged from 77 to 91%. The trend in this study
was that high concentrations of quinidine have the greatest
negative predictive capability (91%). This predictive ca-
pability was similar to that (87%) reported by Waxman et
al. (6) with higher concentrations of procainamide and that
(73%) reported by Rae et al. (7), who also used higher
concentration of procainamide. The present data interpreted
in the context of these earlier studies suggest the general
principle that the screening capability of nonresponse to a
class IA antiarrhythmic agent is concentration-dependent
rather than drug specific. Thus the negative concordance
rates observed with high concentrations of class IA agents
may be clinically relevant.
Discordance of number of extrastimuli used. These
high negative concordance rates contrast with the low pos-
itive concordance rates noted earlier from noninducibility.
However, antiarrhythmic efficacy is not a dichotomy. The
overall negative concordance rates, represented by persistent
inducibility of ventricular tachycardia, fail to recognize the
continuum of grades of inducibility. Therefore, assessment
of the similarity or dissimilarity of these three drugs could
be improved by analyzing grades of inducibility separated
into I) easier to induce, 2) inducibility unchanged, and 3)
harder to induce. The definitions used in our study to explore
this notion are arbitrary but the concept of grades of in-
ducibility is supported by the observation that an increase
in the number of extrastimuli needed to induce a ventricular
tachyarrhythmia indicates an antiarrhythmic effect (20). We
have previously shown (II) that site of stimulation can be
an important factor for inducibility of ventricular tachycar-
dia in the drug-free state. A second stimulation site was not
examined during drug therapy in our study and its impor-
tance to these definitions is unknown. The concordance of
each of these possible negative results ranged from 0 to 14%
for all three drugs in our study and from 25 to 59% for any
two of the three drugs. These values are less than
are the chances that the same number of extrastimuli would
be used to induce ventricular tachycardia/fibrillation on all
three of three successive drug-free studies (50%) or any two
of three successive drug-free studies (97%). Thus the high
overall negative concordance rate reported here and else-
where (6,7) likely overestimates similarities in antiarrhyth-
mic inefficacy of these three drugs.
Other electrophysiologic effects. When data from all
the patients were averaged, there were only minor quanti-
tative differences in the effects of the three drugs on other
electrophysiologic measurements. These differences are
probably explained by the observation that equally effective
serum concentrations of all three drugs were not achieved
in each case. Nevertheless, when patients were categorized
into responders (noninducible) and nonresponders (remain
inducible), at least quantitative discordance among some of
the other electrophysiologic effects was noted. These data
imply that there is a complex and incompletely understood
relation between antiarrhythmic response and other electro-
physiologic effects.
Conclusion
Continued ventricular tachycardia inducibility with high
concentrations of anyone of these three class IA drugs is
highly predictive of continued inducibility on either of the
other two. Nevertheless, the clinical utility of this result
should not obscure the observation that antiarrhythmic ef-
ficacies of procainamide, disopyramide and quinidine are
discordant, even though the three drugs have the same gen-
eral effects on other electrophysiologic measurements. Fur-
thermore, the effects on other electrophysiologic measure-
ments also become quantitatively discordant when patients
are classified into responders and nonresponders.
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